You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
方達控股(01521.HK)擬不超555萬美元收購一家藥物代謝研究機構全部股權
格隆匯 11-04 16:40

格隆匯11月4日丨方達控股(01521.HK)公告,於2019年10月31日,公司全資附屬公司Frontage Laboratories,Inc.與RMI的權益持有人Phillip Tiller及Xiao (Sean) Yu訂立股權購買協議。據此,Frontage Labs同意以不超過555萬美元的代價購買目前由RMI權益持有人持有的全部股權,其實際金額將根據RMI未來連續三年的表現及購買協議中規定的公式釐定。

RMI為一家位於美國賓夕法尼亞州的合同研究機構,主要從事為製藥及生物技術公司提供定量及定性藥物代謝服務。

RMI為其客户羣提供多樣服務,包括全方位的代謝物分析及監定服務,如早期發現柔點分析、晚期發現跨物種比較及臨牀前動物放射性標記質量平衡研究。RMI利用最先進的技術(如高解析質譜儀)在新治療劑的發現及開發階段進行高度專業化及高需求的研究。除了提供核心代謝物監定╱分析服務外,該機構亦進行其他代謝相關研究,包括但不限於發現生物分析(小分子及大分子)、代謝穩定性、CYP/UGT代謝表型及抑制研究。

RMI成立超過十年,在客户對代謝物分析╱監定的需求方面享有首選機構的聲譽。於收購事項完成後,集團將透過更多的科學家、設備及設施擴大其產能,以用於向其客户提供現有及全新的服務,有效擴大集團目前在此特定領域服務的客户羣,可望提高集團透過此高度專業化服務產生收入。

PhillipTiller及Xiao(Sean)Yu為着名的藥物代謝科學家,已於美國建立穩固的客户羣。彼等將於收購事項完成後留任公司,並協助集團於中國建立自RMI收購的服務。收購事項將加速集團於美國及中國建立"藥物代謝卓越中心"。合併後的資源將推動集團在向其製藥行業中現有及新客户提供代謝服務方面,取得全球領先的地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account